首页> 外文期刊>Melanoma research >Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival
【24h】

Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival

机译:恶性黑色素瘤中的小眼症转录因子预测隐匿性前哨淋巴结转移和生存

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Microphthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. We previously reported that Mitf expression, as detected by immunohistochemical analysis, is an independent prognostic marker in patients with intermediate-thickness melanoma. However, the clinical significance of Mitf expression in melanoma is not well delineated. In this prospective study, we attempted to demonstrate the correlation between Mitf expression in primary melanoma and the sentinel lymph node status and prognosis. We prospectively examined primary cutaneous melanomas from 94 patients undergoing nodal staging by sentinel lymph node biopsy. We quantified the percentage of tumor cells whose nuclei stained with the Mitf antibody visually. Survival curves were generated using the Kaplan-Meier method. The correlation between Mitf expression and nodal status was evaluated using the Mann-Whitney U-test. Here we demonstrate that Mitf expression is directly correlated with both disease-free survival (DFS) and overall survival (OS) over a median follow-up of 28.5 months. The mean DFS and OS in the eight patients whose melanomas did not stain positive for Mitf were 15.75 +/- 3.36 months (median, 12 months) and 38.17 +/- 5.18 months (median, 29 months), respectively. These results are significantly lower than those for patients who showed evidence of Mitf expression, in whom the mean DFS and OS were 66.1 +/- 4.03 months (median, not reached, P=0.0001) and 66.75 +/- 38.17 months (median, not reached, P=0.0001), respectively. The mean DFS and OS with greater than 25% (67 patients) of the melanoma cells staining positive for Mitf expression were 78.37 +/- 2.78 and 82.38 +/- 1.6 months, respectively, compared with 26.37 +/- 3.2 months (P=0.0001) and 44.53 +/- 4.5 months (P=0.0001), respectively, with up to 25% (27 patients) of cells stained positive for Mitf expression. In addition, there was a significant relationship between Mitf expression and nodal status, as evaluated by sentinel node biopsy. For example, none of the melanomas with greater than 50% Mitf expression had a positive sentinel node biopsy. Our study shows that expression of the molecular marker Mitf in primary cutaneous melanomas is a useful tool in assessing lymph node status. Mitf immunostaining in the primary tumor serves as a reliable predictor of occult lymph node metastases, as well as a favorable prognosticator of DFS and OS in melanoma patients. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
机译:小眼症转录因子(Mitf)参与黑素细胞的发育和分化。我们以前曾报道过,通过免疫组织化学分析检测到的Mitf表达是中层黑色素瘤患者的独立预后标志物。但是,Mitf表达在黑色素瘤中的临床意义尚不明确。在这项前瞻性研究中,我们试图证明原发性黑色素瘤中Mitf表达与前哨淋巴结状态和预后之间的相关性。我们前哨淋巴结活检前瞻性检查了94例接受淋巴结分期的患者的原发性皮肤黑色素瘤。我们量化了其核被肉眼可见的Mitf抗体染色的肿瘤细胞的百分比。使用Kaplan-Meier方法产生存活曲线。使用Mann-Whitney U检验评估Mitf表达与淋巴结状态之间的相关性。在这里,我们证明Mitf的表达与中位随访28.5个月的无病生存期(DFS)和总体生存期(OS)直接相关。在八名黑素瘤未对Mitf染色阳性的患者中,平均DFS和OS分别为15.75 +/- 3.36个月(中位数为12个月)和38.17 +/- 5.18个月(中位数为29个月)。这些结果显着低于显示Mitf表达证据的患者,后者的平均DFS和OS为66.1 +/- 4.03个月(中位数,未达到,P = 0.0001)和66.75 +/- 38.17个月(中位数,未达到,P = 0.0001)。 Mitf表达阳性的黑色素瘤细胞中25%以上(67例)的平均DFS和OS分别为78.37 +/- 2.78和82.38 +/- 1.6个月,而26.37 +/- 3.2个月(P =分别为0.0001)和44.53 +/- 4.5个月(P = 0.0001),其中多达25%(27例患者)的细胞Mitf表达染色呈阳性。此外,通过前哨淋巴结活检评估,Mitf表达与淋巴结状态之间存在显着关系。例如,没有超过50%Mitf表达的黑色素瘤前哨淋巴结活检阳性。我们的研究表明,分子标记物Mitf在原发性皮肤黑色素瘤中的表达是评估淋巴结状态的有用工具。原发性肿瘤中的Mitf免疫染色可作为黑色素瘤患者隐匿性淋巴结转移的可靠预测指标,以及DFS和OS的良好预后指标。版权所有(C)2015 Wolters Kluwer Health,Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号